Anglin Robert M 4
4 · ROCHESTER MEDICAL CORPORATION · Filed Sep 9, 2010
Insider Transaction Report
Form 4
Anglin Robert M
VP Quality & Regulatory
Transactions
- Sale
Common Stock
2010-09-07$8.86/sh−8,000$70,851→ 600 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-09-07−8,000→ 2,000 totalExercise: $2.34Exp: 2011-04-06→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2010-09-07$2.34/sh+8,000$18,752→ 8,600 total
Holdings
- 8,000
Stock Option (Right to Buy)
Exercise: $2.17Exp: 2011-10-16→ Common Stock (8,000 underlying) - 10,000
Stock Option (Right to Buy)
Exercise: $11.91From: 2007-11-29Exp: 2016-11-29→ Common Stock (10,000 underlying) - 10,000
Stock Option (Right to Buy)
Exercise: $12.27From: 2011-01-28Exp: 2020-01-28→ Common Stock (10,000 underlying) - 4,000
Stock Option (Right to Buy)
Exercise: $4.63Exp: 2014-01-02→ Common Stock (4,000 underlying) - 5,000
Stock Option (Right to Buy)
Exercise: $10.89From: 2009-02-12Exp: 2018-02-12→ Common Stock (5,000 underlying) - 20,000
Stock Option (Right to Buy)
Exercise: $11.27From: 2010-02-03Exp: 2019-02-03→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]The price in Column 4 is a weighted average. The prices actually received ranged from $8.85 to $8.861. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F2]Currently 100% vested.
- [F3]Vest as to 25% annual cumulative installments beginning one year from date of grant, beginning the date shown.